Bial

Bial

Portugal - Coronado
Biotechnology
WebsiteLinkedInCareers Page

Focus: Small Molecules, Vaccines

Bial is a life sciences company focused on Small Molecules, Vaccines.

Infectious DiseasesVaccines
Open Jobs
0

Pipeline & Clinical Trials

Opicapone 50 mg
Parkinson Disease
N/A
Clinical Trials (1)
NCT07403799REal-life ON PARKinson's - ITaly (REONPARK-IT)
N/A
N/A
Clinical Trials (1)
NCT01532726Eslicarbazepine Acetate as Add-On Treatment to One Baseline Antiepileptic Drug (ESLADOBA)
N/A
Hypnosis group intervention
Cancer
N/A
Clinical Trials (1)
NCT04873661Cognitive Trance, Hypnosis and Meditation in Oncology
N/A
N/A
Clinical Trials (1)
NCT03959540Safety and Effectiveness of Opicapone Plus Standard of Care in Elderly Patients With Parkinson's Disease
N/A
Gratitude letter
Positive Emotions
N/A
Clinical Trials (1)
NCT05133063The Impact of a Gratitude Intervention on Stress Reactivity
N/A
N/A
Clinical Trials (1)
NCT02965612Specific Immunotherapy for Allergic Child
N/A
N/A
Clinical Trials (1)
NCT07145190SL-START - SubLingual Apomorphine Schemes of TitrAtion in Real-world Treatment
N/A
BIA 2-093
Epilepsy
Phase 1
Clinical Trials (1)
NCT02283814A Open-label, Drug Interaction Study Between Eslicarbazepine Acetate and Topiramate
Phase 1
BIA 9-1067
Parkinson
Phase 1
Clinical Trials (1)
NCT02305277Relative Bioavailability and Bioequivalence Of Different Formulations of Opicapone in Healthy Volunteers
Phase 1
Phase 1
Clinical Trials (1)
NCT02763800Study to Investigate the Safety, Tolerability, Steady State Pharmacokinetic and Pharmacodynamic Profile of BIA 3-202
Phase 1
Phase 1
Clinical Trials (1)
NCT02170376The Effect of BIA 9-1067 at Steady-state on the Levodopa Pharmacokinetics
Phase 1
Carbon-14 BIA 28-6156
Parkinson Disease
Phase 1
Clinical Trials (1)
NCT05220072Mass Balance Recovery and Metabolite Identification of Carbon-14 BIA 28-6156
Phase 1
Phase 1
Clinical Trials (1)
NCT02778594Pharmacokinetic-pharmacodynamic Interaction Between BIA 3-202 and Levodopa/Benserazide
Phase 1
Phase 1
Clinical Trials (1)
NCT03097211Effect of BIA 6-512 at Steady-state on the Levodopa Pharmacokinetics With a Single-dose of Levodopa/Benserazide 200/50 mg or With a Single-dose of Levodopa/Benserazide 200/50 mg Plus a Single-dose of Nebicapone 150 mg
Phase 1
Phase 1
Clinical Trials (1)
NCT01536366Effect of BIA 9-1067 on the Pharmacokinetics of Repaglinide
Phase 1
Eslicarbazepine acetate
Epilepsy
Phase 1
Clinical Trials (1)
NCT03116321Bioequivalence of Two Different Sources of Eslicarbazepine Acetate
Phase 1
400 mg of BIA 5-1058
Cardiovascular Diseases
Phase 1
Clinical Trials (1)
NCT04069130Absorption, Distribution, Metabolism and Excretion of [14C] Labelled BIA 5-1058
Phase 1
200 mg BIA 6-512
Parkinson Disease
Phase 1
Clinical Trials (1)
NCT03095105Pharmacokinetic Profile of BIA 6-512 in Healthy Elderly Subjects Versus Healthy Young Subjects
Phase 1
Phase 1
Clinical Trials (1)
NCT04991194Effect of Age-gender on the Pharmacokinetic and Pharmacodynamic Profiles of BIA 5 1058
Phase 1
50 mg BIA 9 1067
Parkinson Disease
Phase 1
Clinical Trials (1)
NCT04265027Bioavailability and Bioequivalence Between Two Active Pharmaceutical Ingredient (API) Sources of Opicapone (OPC)
Phase 1
BIA 2-093
Epilepsy
Phase 1
Clinical Trials (1)
NCT02284854Pharmacokinetic Interaction Study Between Eslicarbazepine Acetate and Carbamazepine
Phase 1
Phase 1
Clinical Trials (1)
NCT03099226Tolerability, Pharmacokinetics and Pharmacodynamics of Multiple Rising Dose Regimens of BIA 5-453
Phase 1
BIA 9-1067
Epilepsy
Phase 1
Clinical Trials (1)
NCT02305329Dosage Form Proportionality of Opicapone To-Be-Marketed Formulation
Phase 1
BIA 2-093
Epilepsy
Phase 1
Clinical Trials (1)
NCT02283788Trial to Evaluate the Effect of Eslicarbazepine Acetate on Cardiac Repolarization
Phase 1
Phase 1
Clinical Trials (1)
NCT01532141Effect of Rasagiline on BIA 9-1067 Pharmacokinetics
Phase 1
Phase 1
Clinical Trials (1)
NCT02169427An Open-label Study in Healthy Male Subjects to Assess the Absorption, Distribution, Metabolism and Excretion of [14C]-Labelled BIA 9-1067 and Metabolites
Phase 1
Phase 1
Clinical Trials (1)
NCT02169466Pharmacokinetic-pharmacodynamic Interaction Between Three Different Single Doses of BIA 9-1067 and a Single-dose of Controlled-release 100/25 mg Levodopa/Benserazide
Phase 1
Phase 1
Clinical Trials (1)
NCT02169414Effect of Three Multiple-dose Regimens of BIA 9 1067 at Steady-state on the Levodopa Pharmacokinetics
Phase 1
Placebo
Epilepsy
Phase 1
Clinical Trials (1)
NCT02171234A Double-blind, Randomised, Placebo-controlled, Rising Multiple Dose Study to Investigate the Safety, Tolerability, Steady State Pharmacokinetic Profile and CNS Effects of BIA 2-093
Phase 1
Phase 1
Clinical Trials (1)
NCT03093389Tolerability and Steady-state Pharmacokinetics of BIA 6-512
Phase 1
Phase 1
Clinical Trials (1)
NCT01532115Effect of BIA 9-1067 on Cardiac Repolarization in Healthy Adult Men and Women
Phase 1
BIA 2-093
Epilepsy
Phase 1
Clinical Trials (1)
NCT01678976Tolerability and Pharmacokinetics of a Single 900 mg Oral Dose of BIA 2-093 and Oxcarbazepine in Healthy Volunteers
Phase 1
BIA 2-093
Epilepsy
Phase 1
Clinical Trials (1)
NCT02777671Effect of Eslicarbazepine Acetate on the Pharmacokinetics of Gliclazide in Healthy Volunteers
Phase 1
BIA 2-093
Epilepsy
Phase 1
Clinical Trials (1)
NCT02281526An Open-label, Multiple-dose, Single-centre Study, Investigating the Pharmacokinetics of BIA 2-093
Phase 1
Phase 1
Clinical Trials (1)
NCT04675944Effect of BIA 5-1058 on the Steady State Pharmacokinetics of Treprostinil
Phase 1
Phase 1
Clinical Trials (1)
NCT02151994Safety, Tolerability, Pharmacokinetic, Including Food Interaction, and Pharmacodynamic Profile of BIA 5-1058.
Phase 1
Phase 1
Clinical Trials (1)
NCT04991207Effect of BIA 5-1058 400 mg on the Steady State Pharmacokinetics of Bosentan
Phase 1
eslicarbazepine acetate and Microginon®
Partial Epilepsy
Phase 1
Clinical Trials (1)
NCT00898560Effect of Repeat Administration of Eslicarbazepine Acetate on the Pharmacokinetics of a Combined Oral Contraceptive
Phase 1
Phase 1
Clinical Trials (1)
NCT01520987Pharmacokinetics of BIA 9-1067 in Healthy Japanese and Caucasian Subjects
Phase 1
Phase 1
Clinical Trials (1)
NCT04994860Effect of BIA 5-1058 400 mg on the Steady State Pharmacokinetics of Sildenafil
Phase 1
BIA 6-512 400 mg
Parkinson Disease
Phase 1
Clinical Trials (1)
NCT03095092Effect of Food on BIA 6-512 (Trans-resveratrol)
Phase 1
Phase 1
Clinical Trials (1)
NCT00971295Effect of Eslicarbazepine Acetate on the Pharmacokinetics of Metformin in Healthy Volunteers
Phase 1
Phase 1
Clinical Trials (1)
NCT01533077Pharmacokinetic Interaction Between BIA 9-1067 and Standard-release Levodopa/Carbidopa
Phase 1
Phase 1
Clinical Trials (1)
NCT02169440Effect of BIA 9-1067 on the Pharmacokinetics and Pharmacodynamics of Warfarin
Phase 1
BIA 5-453
Hypertension
Phase 1
Clinical Trials (1)
NCT02845037Tolerability, Pharmacokinetics and Dopamine ß-hydroxylase (DßH) Inhibition Profile of BIA 5-453
Phase 1
BIA 2-093
Epilepsy
Phase 1
Clinical Trials (1)
NCT02284828Effects of Eslicarbazepine Acetate (BIA 2-093) on Cognition and Psychomotor Function
Phase 1
Phase 1
Clinical Trials (1)
NCT02763787Safety, Tolerability, Pharmacokinetics (Including Food Interaction), and Pharmacodynamics of BIA 3-202
Phase 1
Phase 1
Clinical Trials (1)
NCT02071810Tolerability, Pharmacokinetics and Pharmacodynamics of BIA 9-1067
Phase 1
BIA 2-093
Epilepsy
Phase 1
Clinical Trials (1)
NCT02172742The Effect of BIA 2-093 on the Steady-state Pharmacokinetics of Digoxin
Phase 1
BIA 5-453
Hypertension
Phase 1
Clinical Trials (1)
NCT03090568Bioavailability Study of BIA 5-453
Phase 1

Open Jobs (0)

No open positions listed yet. Check their careers page directly.

Interview Prep Quick Facts
Portfolio: 50 clinical trials